CONCORD, Mass.--(BUSINESS WIRE)--ClearB Therapeutics, Inc., a company developing CLB-3000, a therapeutic vaccine designed to drive functional cure of hepatitis B, announced today that two abstracts were accepted for poster presentation at the European Association for the Study of the Liver (EASL) International Liver Congress (ILC) 2023, taking place in Vienna, Austria June 21 - 24, 2023.
“As we continue to progress our therapeutic vaccine candidate, CLB-3000, toward first in human trials, we are excited to share our preclinical data with the Hepatitis B community” said Chris Stevens, MD, CMO for the company. “Chronic Hepatitis B (CHB) infection remains a substantial global health care problem in need of effective antiviral and immunomodulatory therapies likely in combination. We believe that re-education of patients’ immune systems with ClearB’s therapeutic vaccine could become an important component of such treatment regimens.”
Abstract Number: 2515 / SAT-197
Abstract Title: Therapeutic vaccine candidate CLB-3000 (CLB-405 and CLB-505 adjuvanted with Alhydrogel): a Good Laboratory Practice (GLP)-compliant 15-week intramuscular toxicity study in rabbits with a 4-week recovery
Date: Saturday, June 24, 2023
Time: 9:00 AM GMT+1
Presenter Name: Dr. Aileen Rubio, ClearB Therapeutics
Abstract Number: 2543 / SAT-191
Abstract Title: A monoclonal antibody 4G2 exhibits anti-viral activity in persistent HBV infection mouse models
Date: Saturday, June 24, 2023
Time: 9:00 AM GMT+1
Presenter Name: Dr. Aditi Deshpande, ClearB Therapeutics
For more information regarding EASL 2023 please visit
EASL Congress 2023 - The International Liver Congress
About ClearB Therapeutics
ClearB Therapeutics was co-founded in 2017 by Morningside Ventures in collaboration with Professor Stephen Locarnini and the Victoria Infectious Diseases Reference Laboratory in Melbourne, Australia. ClearB is working to develop therapeutic vaccines designed to drive functional cure of hepatitis B. The work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B. For more information, please visit https://clearbtherapeutics.com/.
About Morningside Ventures: Morningside was founded in 1986 by the Chan family, to make private equity and venture capital investments in North America, Europe, and Asia Pacific. In the life sciences, Morningside specializes in early-stage (pre-clinical through human proof-of-concept) investments in biopharmaceutical products. They partner with academic founders and entrepreneurs to build world-class companies that want to markedly improve the current state of medicine today and ultimately, the lives of patients. Morningside's focus is to invest in excellent biomedical research, where a significant body of knowledge has been gathered and there is a plausible path forward in clinical development. Their mission is to contribute to making a meaningful, positive impact on the prevention or treatment of human disease, and believe that so long as this is achieved, commercial success will follow.
